The Journal of Immunology, Vol 159, Issue 10 4753-4761, Copyright © 1997 by American Association of Immunologists

ARTICLES

Derivation of HLA-A11/Kb transgenic mice: functional CTL repertoire and recognition of human A11-restricted CTL epitopes [published erratum appears in J Immunol 1999 Mar 1;162(5):3104]

J Alexander, C Oseroff, J Sidney, P Wentworth, E Keogh, G Hermanson, FV Chisari, RT Kubo, HM Grey and A Sette
Cytel Corporation, San Diego, CA 92121, USA. alexander@cytelcorp.com

Transgenic mice expressing chimeric human (alpha1 and alpha2 HLA-A11 domains) and murine (alpha3, transmembrane, and cytoplasmic H-2Kb domains) class I molecules were derived. These mice were used as a model system to study the immunogenicity of human CTL epitopes and also to examine the aspects of Ag processing differences of mice vs man. Immunization of these mice with seven known HLA-A11-restricted CTL epitopes emulsified in IFA resulted in vigorous specific CTL responses. A larger panel of 45 A11-binding peptides was used to examine the relationship between immunogenicity in the HLA-A11/Kb transgenic mice and HLA-A11 binding capacity. Twenty-one of 28 (75%) peptides with high binding affinities (50% inhibitory concentration (IC50), 2-50 nM) and 7 of 13 (54%) intermediate binding peptides (IC50, 50-500 nM range) were immunogenic. In parallel, 19 of these peptides were used for in vitro primary immunizations of PBMC derived from HLA-A11 healthy human donors. It was found that 8 of 8 peptides that were able to elicit CTL in primary human in vitro cultures were also immunogenic in HLA-A11/Kb mice. Finally, HLA-A11/Kb transgenic mice were found to generate an A11/Kb restricted CTL response following immunization with influenza virus A/PR/8/34, suggesting that, at least to some extent, A11 epitopes are generated by transgenic mice as a result of natural in vivo processing and presentation.

This article has been cited by other articles:

				E. Depla, A. Van der Aa, B. D. Livingston, C. Crimi, K. Allosery, V. De Brabandere, J. Krakover, S. Murthy, M. Huang, S. Power, et al. Rational Design of a Multiepitope Vaccine Encoding T-Lymphocyte Epitopes for Treatment of Chronic Hepatitis B Virus Infections J. Virol., January 1, 2008; 82(1): 435 - 450. [Abstract] [Full Text] [PDF]

				F. Bihl, N. Frahm, L. Di Giammarino, J. Sidney, M. John, K. Yusim, T. Woodberry, K. Sango, H. S. Hewitt, L. Henry, et al. Impact of HLA-B Alleles, Epitope Binding Affinity, Functional Avidity, and Viral Coinfection on the Immunodominance of Virus-Specific CTL Responses J. Immunol., April 1, 2006; 176(7): 4094 - 4101. [Abstract] [Full Text] [PDF]

				V. Pasquetto, H.-H. Bui, R. Giannino, F. Mirza, J. Sidney, C. Oseroff, D. C. Tscharke, K. Irvine, J. R. Bennink, B. Peters, et al. HLA-A*0201, HLA-A*1101, and HLA-B*0702 Transgenic Mice Recognize Numerous Poxvirus Determinants from a Wide Variety of Viral Gene Products J. Immunol., October 15, 2005; 175(8): 5504 - 5515. [Abstract] [Full Text] [PDF]

				D. M. McKinney, R. Skvoretz, B. D. Livingston, C. C. Wilson, M. Anders, R. W. Chesnut, A. Sette, M. Essex, V. Novitsky, and M. J. Newman Recognition of Variant HIV-1 Epitopes from Diverse Viral Subtypes by Vaccine-Induced CTL J. Immunol., August 1, 2004; 173(3): 1941 - 1950. [Abstract] [Full Text] [PDF]

				H. Takedatsu, S. Shichijo, K. Katagiri, H. Sawamizu, M. Sata, and K. Itoh Identification of Peptide Vaccine Candidates Sharing among HLA-A3+, -A11+, -A31+, and -A33+ Cancer Patients Clin. Cancer Res., February 1, 2004; 10(3): 1112 - 1120. [Abstract] [Full Text] [PDF]

				C. C. Wilson, D. McKinney, M. Anders, S. MaWhinney, J. Forster, C. Crimi, S. Southwood, A. Sette, R. Chesnut, M. J. Newman, et al. Development of a DNA Vaccine Designed to Induce Cytotoxic T Lymphocyte Responses to Multiple Conserved Epitopes in HIV-1 J. Immunol., November 15, 2003; 171(10): 5611 - 5623. [Abstract] [Full Text] [PDF]

				C. La Rosa, Z. Wang, J. C. Brewer, S. F. Lacey, M. C. Villacres, R. Sharan, R. Krishnan, M. Crooks, S. Markel, R. Maas, et al. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice Blood, November 15, 2002; 100(10): 3681 - 3689. [Abstract] [Full Text] [PDF]

				J. Alexander, C. Oseroff, C. Dahlberg, M. Qin, G. Ishioka, M. Beebe, J. Fikes, M. Newman, R. W. Chesnut, P. A. Morton, et al. A Decaepitope Polypeptide Primes for Multiple CD8+ IFN-{gamma} and Th Lymphocyte Responses: Evaluation of Multiepitope Polypeptides as a Mode for Vaccine Delivery J. Immunol., June 15, 2002; 168(12): 6189 - 6198. [Abstract] [Full Text] [PDF]

				T. M. Allen, B. R. Mothé, J. Sidney, P. Jing, J. L. Dzuris, M. E. Liebl, T. U. Vogel, D. H. O'Connor, X. Wang, M. C. Wussow, et al. CD8+ Lymphocytes from Simian Immunodeficiency Virus-Infected Rhesus Macaques Recognize 14 Different Epitopes Bound by the Major Histocompatibility Complex Class I Molecule Mamu-A*01: Implications for Vaccine Design and Testing J. Virol., January 15, 2001; 75(2): 738 - 749. [Abstract] [Full Text]

				A. D. Sette, C. Oseroff, J. Sidney, J. Alexander, R. W. Chesnut, K. Kakimi, L. G. Guidotti, and F. V. Chisari Overcoming T Cell Tolerance to the Hepatitis B Virus Surface Antigen in Hepatitis B Virus-Transgenic Mice J. Immunol., January 15, 2001; 166(2): 1389 - 1397. [Abstract] [Full Text] [PDF]

				S. H. Borenstein, J. Graham, X.-L. Zhang, and J. W. Chamberlain CD8+ T Cells Are Necessary for Recognition of Allelic, But Not Locus-Mismatched or Xeno-, HLA Class I Transplantation Antigens J. Immunol., September 1, 2000; 165(5): 2341 - 2353. [Abstract] [Full Text] [PDF]

				G. Y. Ishioka, J. Fikes, G. Hermanson, B. Livingston, C. Crimi, M. Qin, M. France del Guercio, C. Oseroff, C. Dahlberg, J. Alexander, et al. Utilization of MHC Class I Transgenic Mice for Development of Minigene DNA Vaccines Encoding Multiple HLA-Restricted CTL Epitopes J. Immunol., April 1, 1999; 162(7): 3915 - 3925. [Abstract] [Full Text] [PDF]

				A. Geluk, V. Taneja, K. E. van Meijgaarden, E. Zanelli, C. Abou-Zeid, J. E. R. Thole, R. R. P. de Vries, C. S. David, and T. H. M. Ottenhoff Identification of HLA class II-restricted determinants of Mycobacterium tuberculosis-derived proteins by using HLA-transgenic, class II-deficient mice PNAS, September 1, 1998; 95(18): 10797 - 10802. [Abstract] [Full Text] [PDF]